Block copolymer micelles for the encapsulation and delivery of amphotericin B

被引:75
作者
Lavasanifar, A
Samuel, J
Sattari, S
Kwon, GS
机构
[1] Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA
[2] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
关键词
block copolymer micelles; amphotericin B; systemic fungal diseases; drug delivery; hemolysis;
D O I
10.1023/A:1015127225021
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To assess the effect of fatty acid substitution of a micelle-forming poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide) (PEO-b-PHSA) on the encapsulation, hemolytic properties and antifungal activity of amphotericin B (AmB). Methods. PEO-b-PHSA with three levels of stearic acid substitution were synthesized and used to encapsulate AmB by a solvent evaporation method. Size exclusion chromatography and UV spectroscopy were used to confirm and measure levels of encapsulated AmB. The hemolytic activity of encapsulated AmB toward human red blood cells and its minimum inhibitory concentration against Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans were obtained and compared to AmB alone. Results. An increase in the level of stearic acid substitution on PEO-b-PHSA improved the encapsulation of AmB while reducing its hemolytic activity. PEO-b-PHSA micelles having 50% and 70% stearic acid substitution (mol fatty acid: mol reacted and unreacted hydroxyls) were completely non-hemolytic at 22 mug/ml. At 11% stearic acid substitution, AmB caused 50% hemolysis at 1 mug/ml. AmB in PEO-b-PHSA micelles was as effective as AmB alone against pathogenic fungi. Conclusions. PEO-b-PHSA micelles with a high level of stearic acid side chain substitution can effectively solubilize AmB, reduce its hemolytic activity yet retain its potent antifungal effects.
引用
收藏
页码:418 / 422
页数:5
相关论文
共 14 条
[1]   Nano-engineering block copolymer aggregates for drug delivery [J].
Allen, C ;
Maysinger, D ;
Eisenberg, A .
COLLOIDS AND SURFACES B-BIOINTERFACES, 1999, 16 (1-4) :3-27
[2]   INHIBITION OF THE INTERACTION BETWEEN LIPOPROTEINS AND AMPHOTERICIN-B BY SOME DELIVERY SYSTEMS [J].
BARWICZ, J ;
GAREAU, R ;
AUDET, A ;
MORISSET, A ;
VILLIARD, J ;
GRUDA, I .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 181 (02) :722-728
[3]   Carrier effects on biological activity of amphotericin B [J].
Brajtburg, J ;
Bolard, J .
CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (04) :512-+
[4]   EFFECT OF THE AGGREGATION STATE OF AMPHOTERICIN-B ON ITS INTERACTION WITH ERGOSTEROL [J].
GRUDA, I ;
DUSSAULT, N .
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1988, 66 (03) :177-183
[5]   Soluble self-assembled block copolymers for drug delivery [J].
Kwon, GS ;
Okano, T .
PHARMACEUTICAL RESEARCH, 1999, 16 (05) :597-600
[6]   BLOCK-COPOLYMER MICELLES AS LONG-CIRCULATING DRUG VEHICLES [J].
KWON, GS ;
KATAOKA, K .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (2-3) :295-309
[7]   The effect of alkyl core structure on micellar properties of poly(ethylene oxide)-block-poly(L-aspartamide) derivatives [J].
Lavasanifar, A ;
Samuel, J ;
Kwon, GS .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2001, 22 (02) :115-126
[8]   Micelles self-assembled from poly(ethylene oxide)-block-poly(N-hexyl stearate L-aspartamide) by a solvent evaporation method:: effect on the solubilization and haemolytic activity of amphotericin B [J].
Lavasanifar, A ;
Samuel, J ;
Kwon, GS .
JOURNAL OF CONTROLLED RELEASE, 2001, 77 (1-2) :155-160
[9]  
Lavasanifar A, 2000, J BIOMED MATER RES, V52, P831, DOI 10.1002/1097-4636(20001215)52:4<831::AID-JBM29>3.0.CO
[10]  
2-K